Bayer Pharma Aktiengesellschaft

Jorma Haßfeld

Karl-Heinz Schlemmer

Joachim Schuhmacher

Susanne Röhrig

Michael Sperzel

Nils Burkhardt

Christian Stegmann

Manuel Ellermann

Tom Kinzel

Maria Köllnberger

Kristin Beyer

Johannes-Peter Stasch

Andreas Knorr

Frank Wunder

Alexander Straub

Volkhart Min-Jian Li

Markus Follmann

Johannes Köbberling

Matthias Werner

Yolanda Cancho-Grande

Alexandros Vakalopoulos

Gorden Redlich

Rolf Jautelat

Niels Lindner

Yolanda Cancho Grande

Philipp Buchgraber

Ingo Hartung

Eva Maria Becker-Pelster

Dirk Schneider

Alexey Gromov

Jan Stampfuß

Eva-Maria Becker-Pelster

Markus Follman

Gaelle Valot

Imke Meyer

Jörg Heiermann

Willem Jan Hengeveld

The present application relates to novel substituted (aza)pyridopyrazolopyrimidinones and indazolopyrimidinones, to processes for their preparation, the compounds for use alone or in combinations in a method for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of acute and recurrent bleeding in patients with or without underlying hereditary or acquired bleeding disorders, wherein the bleeding is associated with a disease or medical intervention selected from the group consisting of menorrhagia, postpartum hemorrhage, hemorrhagic shock, trauma, surgery, transplantation, stroke, liver diseases, hereditary angioedema, nosebleed, and synovitis and cartilage damage following hemarthrosis.

(Aza)pyridopyrazolopyrimidinones and indazolopyrimidinones and their use

The present application relates to novel substituted imidazo[1,2-a]pyridine-3-carboxamides of the general formula (I) to processes for their preparation, to their use alone or in combinations for the treatment and/or prophylaxis of diseases and to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of cardiovascular disorders.

Amino-substituted imidazo[1,2-A] pyridinecarboxamides and their use

The present application relates to novel substituted piperidinylpyrazolopyrimidinones, to processes for their preparation, the compounds for use alone or in combinations in a method for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of acute and recurrent bleeding in patients with or without underlying hereditary or acquired hemostatic disorders, wherein the bleeding is associated with a disease or medical intervention selected from the group consisting of heavy menstrual bleeding, postpartum hemorrhage, hemorrhagic shock, hemorrhagic cystitis, gastrointestinal hemorrhage, trauma, surgery, transplantation, stroke, liver diseases, hereditary angioedema, nosebleed, and synovitis and cartilage damage following hemarthrosis.

Piperidinylpyrazolopyrimidinones and their use

Growing community of inventors

Düsseldorf, Germany

Jorma Haßfeld